Jun 20 |
Barclays cuts Prelude to underweight, cites lack of near-term catalysts
|
Jun 20 |
Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls
|
Jun 3 |
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
|
May 30 |
Prelude Therapeutics files for $400M mixed securities shelf
|
May 9 |
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
|
May 7 |
Prelude Therapeutics GAAP EPS of -$0.42
|
May 7 |
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
Apr 13 |
Several Insiders Invested In Prelude Therapeutics Flagging Positive News
|
Apr 9 |
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
|
Mar 5 |
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
|